Movement Alert｜Stryker Rises 3.99% in Regular Trading, Oversold Rebound After Q2 Earnings Selloff Amid Broad Medical Device Sector Strength

Market Focus08-03

On August 3, Stryker rose 3.99% in regular trading, trading at approximately $334.23/share, with turnover of $103 million. The rebound follows a sharp post-earnings selloff that saw shares drop over 8% after the company reported Q2 results on July 30.

While Stryker's Q2 adjusted EPS of $3.69 beat consensus of $3.49 by 5.73% and net sales of $6.589 billion slightly topped the $6.579 billion estimate, its core MedSurg and Neurotechnology segment posted revenue of $3.6 billion, missing the $3.72 billion expectation. Additionally, full-year adjusted EPS guidance was only narrowed to $14.95-$15.10 from $14.90-$15.10, a minimal raise that disappointed investors given the strong Q2 beat. After consecutive sessions of selling pressure, the stock is now rebounding alongside broad healthcare equipment sector strength, with Intuitive Surgical up 6.02%, Boston Scientific up 3.98%, and DexCom up 3.98%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1114594872?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-03 22:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1114594872","market":"us","top_or_hot":-1,"title":"Movement Alert｜Stryker Rises 3.99% in Regular Trading, Oversold Rebound After Q2 Earnings Selloff Amid Broad Medical Device Sector Strength","media":"Market Focus","content":"<p><p>On August 3, Stryker rose 3.99% in regular trading, trading at approximately $334.23/share, with turnover of $103 million. The rebound follows a sharp post-earnings selloff that saw shares drop over 8% after the company reported Q2 results on July 30.</p><p>While Stryker's Q2 adjusted EPS of $3.69 beat consensus of $3.49 by 5.73% and net sales of $6.589 billion slightly topped the $6.579 billion estimate, its core MedSurg and Neurotechnology segment posted revenue of $3.6 billion, missing the $3.72 billion expectation. Additionally, full-year adjusted EPS guidance was only narrowed to $14.95-$15.10 from $14.90-$15.10, a minimal raise that disappointed investors given the strong Q2 beat. After consecutive sessions of selling pressure, the stock is now rebounding alongside broad healthcare equipment sector strength, with Intuitive Surgical up 6.02%, Boston Scientific up 3.98%, and DexCom up 3.98%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Stryker Rises 3.99% in Regular Trading, Oversold Rebound After Q2 Earnings Selloff Amid Broad Medical Device Sector Strength</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Stryker Rises 3.99% in Regular Trading, Oversold Rebound After Q2 Earnings Selloff Amid Broad Medical Device Sector Strength\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-03 22:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 3, Stryker rose 3.99% in regular trading, trading at approximately $334.23/share, with turnover of $103 million. The rebound follows a sharp post-earnings selloff that saw shares drop over 8% after the company reported Q2 results on July 30.</p><p>While Stryker's Q2 adjusted EPS of $3.69 beat consensus of $3.49 by 5.73% and net sales of $6.589 billion slightly topped the $6.579 billion estimate, its core MedSurg and Neurotechnology segment posted revenue of $3.6 billion, missing the $3.72 billion expectation. Additionally, full-year adjusted EPS guidance was only narrowed to $14.95-$15.10 from $14.90-$15.10, a minimal raise that disappointed investors given the strong Q2 beat. After consecutive sessions of selling pressure, the stock is now rebounding alongside broad healthcare equipment sector strength, with Intuitive Surgical up 6.02%, Boston Scientific up 3.98%, and DexCom up 3.98%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SYK","symbol_name":"史赛克","start_time":0,"source_url":"","article_id":"1114594872","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1114594872","pubTimestamp":1785765662,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 3, Stryker rose 3.99% in regular trading, trading at approximately $334.23/share, with turnover of $103 million. The rebound follows a sharp post-earnings selloff that saw shares drop over...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SYK":"史赛克"},"translate_title":"走势警报|史赛克在常规交易中上涨 3.99%，在医疗器械行业普遍走强的情况下第二季度盈利抛售后超卖反弹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SYK":1},"content_text":"On August 3, Stryker rose 3.99% in regular trading, trading at approximately $334.23/share, with turnover of $103 million. The rebound follows a sharp post-earnings selloff that saw shares drop over 8% after the company reported Q2 results on July 30.While Stryker's Q2 adjusted EPS of $3.69 beat consensus of $3.49 by 5.73% and net sales of $6.589 billion slightly topped the $6.579 billion estimate, its core MedSurg and Neurotechnology segment posted revenue of $3.6 billion, missing the $3.72 billion expectation. Additionally, full-year adjusted EPS guidance was only narrowed to $14.95-$15.10 from $14.90-$15.10, a minimal raise that disappointed investors given the strong Q2 beat. After consecutive sessions of selling pressure, the stock is now rebounding alongside broad healthcare equipment sector strength, with Intuitive Surgical up 6.02%, Boston Scientific up 3.98%, and DexCom up 3.98%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1114594872","isCrawlerRequest":true}